The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Predictors and outcomes of extramedullary disease in multiple myeloma
Saurabh Zanwar, MD, MBBS, Mayo Clinic, Rochester, MN, outlines the predictors of extramedullary disease (EMD) in patients with multiple myeloma (MM) and highlights the outcomes of these patients when treated with existing myeloma therapies. Current therapeutic approaches yield inferior outcomes in those with EMD, with CAR-T therapy being considered the best of the limited treatment options. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
